The Nasdaq Stock Market is preparing to launch an index made up of companies that focus on neurological disorders, following the flurry of exchange traded funds (ETFs) that have launched in the health sector. Companies included in the Nasdaq NeuroInsights Neurotech Index have a primary focus on the development of drugs, devices and diagnostics to treat brain disorders such as Alzheimer’s, Parkinson’s disease or schizophrenia, reports Toni Clarke for Reuters. It is one of the first indexes to focus solely on this disease category, and it is targeted for institutional and individual investors. This 32-member index has a combined market value of $71 billion. It will be interesting to see how long it takes to launch an ETF that tracks this new index.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.